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Histone methylation plays an important role in regulating gene expression. One such methylation occurs at Lys
79 of histone H3 (H3K79) and is catalyzed by the yeast DOT1 (disruptor of telomeric silencing) and its mammalian
homolog, DOT1L. Previous studies have demonstrated that germline disruption of Dot1L in mice resulted
in embryonic lethality. Here we report that cardiac-specific knockout of Dot1L results in increased mortality rate
with chamber dilation, increased cardiomyocyte cell death, systolic dysfunction, and conduction abnormalities.
These phenotypes mimic those exhibited in patients with dilated cardiomyopathy (DCM). Mechanistic studies
reveal that DOT1L performs its function in cardiomyocytes through regulating Dystrophin (Dmd) transcription
and, consequently, stability of the Dystrophin–glycoprotein complex important for cardiomyocyte viability.
Importantly, expression of a miniDmd can largely rescue the DCM phenotypes, indicating that Dmd is a major
target mediating DOT1L function in cardiomyocytes. Interestingly, analysis of available gene expression data sets
indicates that DOT1L is down-regulated in idiopathic DCM patient samples compared with normal controls.
Therefore, our study not only establishes a critical role for DOT1L-mediated H3K79 methylation in cardiomyo-
cyte function, but also reveals the mechanism underlying the role of DOT1L in DCM. In addition, our study may
open new avenues for the diagnosis and treatment of human heart disease.
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Chromatin is subject to reversible post-translational
modifications that may alter chromatin structure and
function directly, or indirectly through the recruitment of
effector proteins at heterochromatic (silenced) and eu-
chromatic (active) DNA. Histone methylation plays an
important role in regulating transcription at target loci
and is important for X inactivation, cell fate mainte-
nance, and terminal differentiation (Peterson and Laniel
2004; Martin and Zhang 2005; Kouzarides 2007). One
particular histone methylation event occurs at Lys 79
within the globular domain of histone H3 (H3K79) and is
catalyzed by yeast DOT1 (disruptor of telomeric silenc-
ing) and its mammalian homolog, DOT1L (Feng et al.
2002; Lacoste et al. 2002; Ng et al. 2002a; van Leeuwen
et al. 2002). Although DOT1 was originally identified as
a regulator of telomeric silencing (Singer et al. 1998),
more recent studies suggest that DOT1-mediated H3K79
methylation is linked to euchromatic gene transcrip-
tion (Schubeler et al. 2004; Barski et al. 2007; Steger et al.
2008).
In yeast, DOT1 activity is positively regulated during
transcription elongation through Rad6-Bre1 monoubiqui-
tination of H2B (Ng et al. 2002b; Krogan et al. 2003; Wood
et al. 2003). Additionally, DOT1 has been linked to the
meiotic pachytene checkpoint control (San-Segundo and
Roeder 2000) and DNA damage repair (Giannattasio et al.
2005; Wysocki et al. 2005; Conde et al. 2009). However,
the biological function of mammalian DOT1L, particu-
larly in the context of the animal, is less characterized. A
recent study indicates that DOT1L exists in a large pro-
tein complex and regulates the expression of Wingless
target genes (Mohan et al. 2010). We and others demon-
strated previously that mistargeting of DOT1L and sub-
sequent H3K79 hypermethylation play an important role
in leukemic transformation (Okada et al. 2005, 2006;
Mueller et al. 2007; Krivtsov et al. 2008). Most recently,
DOT1L has been shown to regulate the erythroid and
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myeloid lineage switch during differentiation (Feng et al.
2010). In addition, loss-of-function studies revealed a crit-
ical role of DOT1L during mouse embryogenesis, as
germline Dot1l knockout (KO) causes lethality at embry-
onic day 10.5 (E10.5) with growth impairment, yolk sac
angiogenesis defects, and cardiac dilation (Jones et al.
2008).
Congestive heart failure (CHF) is a common manifes-
tation of cardiomyopathy, a disease caused by malfunc-
tion of the heart muscle (Seidman and Seidman 2001;
Liew and Dzau 2004). Dilated cardiomyopathy (DCM) is
characterized by dilation of the left or both ventricles and
reduced contractile function (systolic dysfunction), and is
the most prevalent form of cardiomyopathy (Seidman and
Seidman 2001; Liew and Dzau 2004). Recent studies
suggest that, in addition to genetic alterations, epigenetic
factors also contribute to DCM. For example, several
studies have linked histone acetylation to cardiac hyper-
trophy and DCM (Zhang et al. 2002; Kook et al. 2003;
Montgomery et al. 2007; Ha et al. 2010; Hang et al. 2010).
However, whether histone methylation contributes to
DCM is not clear, although dysregulation of histone
methylation has been linked to a number of human dis-
eases (Feinberg et al. 2002; Handel et al. 2009).
To further characterize the function of DOT1L in the
mouse heart, we generated a cardiomyocyte-specific KO
mouse model using the a-MHC (a-myosin heavy chain)-
Cre line and demonstrate that DOT1L plays an important
role in heart function. We provide evidence suggesting
that dysregulation of Dystrophin in cardiomyocytes is
largely responsible for the phenotypes exhibited in the
Dot1L cardiac conditional KO mice.
Results
Dot1L deficiency in cardiomyocytes does not cause
embryonic lethality
Previous studies demonstrate that germline Dot1l KO
causes lethality at E10.5 with diverse impairments that
include growth retardation, yolk sac angiogenesis defects,
and cardiac dilation (Jones et al. 2008). To understand the
molecular mechanism underlying the embryonic pheno-
types, we took advantage of the fact that the Dot1L
conditional allele contains a promoterless b-geo cassette
(Jones et al. 2008), and analyzed Dot1L expression by
X-gal staining. This study revealed that the heart is one of
the highest Dot1L-expressing organs (Supplemental Fig.
1A). RT-qPCR analysis also indicates that cardiac expres-
sion of Dot1L peaks after birth (Supplemental Fig. 1B).
This Dot1L expression pattern in combination with the
timing of lethality suggests that heart defects might
contribute to the embryonic lethality phenotype.
To explore a role for DOT1L in the heart, we gener-
ated a cardiac-specific conditional KO mouse model by
first crossing DOT1L2lox/+ and DOT1L1lox/+ with the
a-MHC-Cre line (Supplemental Fig. 2A; Abel et al.
1999). Cardiac conditional KO (referred to as CKO here-
after), DOT1L2lox/1lox;a-MHC-Cre, mice were then ob-
tained by crossing DOT1L2lox/+;a-MHC-Cre mice with
DOT1L1lox/+;a-MHC-Cre mice. Cre-mediated deletion
results in removal of 108 amino acids in the catalytic
domain of DOT1L, rendering an enzymatically inactive
DOT1L (Supplemental Fig. 2B). CKO mice were born at
Mendelian ratio (Supplemental Fig. 2C), and recombina-
tion efficiency was verified by RT-qPCR using hearts
derived from newborn, postnatal day 1 (P1) mice (Supple-
mental Fig. 2D). Consistent with loss-of-function of
DOT1L in the CKO hearts, Western blot analysis and
immunostaining using an antibody that recognizes both
di- and trimethylation of H3K79 (H3K79me2/3) demon-
strate loss of H3K79me2/3 in the CKO hearts (Supplemen-
tal Fig. 2E,F). These results suggest that loss-of-function of
DOT1L in cardiomyocytes alone is not sufficient to cause
embryonic lethality.
Dot1L deficiency in cardiomyocytes causes heart
dilation and postnatal lethality
Although CKO mice are born at Mendelian ratio, sudden
death was observed in 50% of the CKO mice within 2 wk
after birth, and the remaining 50% of the CKO mice died
by 6 mo of age (Fig. 1A), indicating that DOT1L has an
important function in postnatal and adult cardiomyo-
cytes. Analysis of the CKO mice revealed severely
enlarged hearts (Fig. 1B) and dilation of both chambers
(Fig. 1C). Consistently, heart to body weight ratios were
also increased in CKO mice compared with that of their
littermate controls (Fig. 1D). The increased heart to body
weight ratio is caused mainly by increased heart weight
(Fig. 1E), as the body weight is not significantly altered
between wild-type and CKO mice (Supplemental Fig. 3A).
To determine whether concentric hypertrophy contrib-
utes to the increase in CKO heart mass, tissue sections
were stained with Laminin antibody followed by measur-
ing cardiomyocyte circumference. Quantification using
ImageJ software indicates that the average cell circum-
ference is not altered in CKO mice (Supplemental Fig.
3B,C), suggesting that the increase in CKO heart mass is
due in part to eccentric hypertrophy. These data collec-
tively indicate that loss of DOT1L function—particularly
its H3K79 methyltransferase activity—in cardiomyo-
cytes results in CHF that is likely due to DCM.
CKO hearts exhibit similar cardiac remodeling
observed in DCM patients
In addition to chamber dilation, gross changes in heart
morphology (such as deviation from an elliptical shape to
a more spherical one and increased heart mass) were also
observed (Fig. 1C,E), indicating that loss-of-function of
DOT1L in cardiomyocytes caused cardiac remodeling.
Since DCM is often accompanied by pathologic remodel-
ing (Cohn et al. 2000), we analyzed the histopathology of
CKO hearts at P10. TUNEL staining revealed a dramatic
increase in apoptotic cell death in CKO hearts compared
with the wild-type control (Fig. 2A). In addition, trans-
mission electron microscopic (TEM) analysis revealed
a significant increase of vacuoles in CKO myocytes (Fig.
2B, panel ii, arrows), suggesting an increase in autophagic
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cell death, consistent with previous studies linking
autophagy to DCM (Knaapen et al. 2001). In addition,
TEM also revealed interstitial fibroblast cells in CKO
heart tissue (Fig. 2B, cf. panels i and iii), indicating that
reactive fibrosis, a common feature of cardiac remodeling
found in DCM (de Leeuw et al. 2001; Luk et al. 2009),
took place in CKO hearts. Additionally, immunostaining
with anti-HSPG2 (also known as Perlecan) shows in-
creased interstitial HSPG2 staining (Fig. 2C, arrowheads)
as well as increased HSPG2 and myofibroblasts lining the
inner left ventricular chamber (Fig. 2C, yellow outlined)
in CKO hearts, supporting the presence of reactive
fibrosis, which is further confirmed by Masson’s tri-
chrome staining (Fig. 2D, blue staining).
Previous studies have established that reactivation of
a fetal gene expression program and increase in cellular
proliferation is concomitant with the degeneration of
cardiomyocytes in DCM (Kajstura et al. 1998; Cohn
et al. 2000; Houweling et al. 2005). Consistent with
the notion that DOT1L deficiency resulted in DCM,
Figure 1. Disruption of DOT1L function
in mouse cardiomyocytes results in heart
dilation and lethality. (A) Dot1L CKO in
mouse heart causes postnatal and adult le-
thality. Survival curves of wild-type (WT),
HET, and CKO mice. Fifty percent of CKO
mice die within the first 2 wk after birth
and the remaining 50% die by 6 mo of age.
(B) CKO hearts are severely enlarged com-
pared with wild type (WT). Shown are wild-
type and CKO hearts harvested from P10
and 5 -mo-old adult mice, respectively. Bar,
1 mm. (C) H&E staining of paraffin tissue
sections indicated that CKO hearts are
enlarged due to ventricular chamber dila-
tion. Bar, 1 mm. (D) CKO mice have in-
creased heart to body weight ratios. Heart
weight (milligrams) to body weight (grams)
ratios were calculated using an analytical
balance. CKO mice have increased ratios
compared with wild-type littermates. (*) P <
0.06; (**) P < 0.006; (***) P < 0.0006. (E)
CKO mice have increased heart weight.
Heart weight (milligrams) was measured
using an analytical balance. (*) P < 0.06.
Figure 2. Disruption of DOT1L function
in mouse cardiomyocytes results in patho-
logic cardiac remodeling. (A) Positive
TUNEL staining (green) merged with DAPI
(blue) demonstrates increased cell death in
CKO hearts (P10; bar, 5 mm). (B) TEM
analysis of P10 hearts demonstrates in-
creased autophagic cell death (cf. panels
i and ii; yellow box is enlarged from panel
ii; vacuoles are indicated by yellow arrows;
bar, 2 mm) and myofibroblast infiltration
(indicated by asterisk [*] in panel iii) in
CKO hearts. Note that myocytes in wild-
type (WT) hearts show tight lateral associ-
ation, whereas myocytes in CKO hearts
have large gaps due to myofibroblast in-
filtration. (C) Increased interstitial ECM,
indicated by staining of the ECM compo-
nent HSPG2 (red), is observed in the CKO
hearts (arrowheads). Increased ECM and myofibroblasts lining the inner left ventricular chamber wall (between the two yellow lines) is
also observed in CKO hearts. Bar, 10 mm. (D) Masson’s trichrome staining of paraffin tissue sections of mouse hearts (5 mo old). Two
enlarged regions are shown (black and yellow boxes). Interstitial fibrosis is seen in CKO hearts, but not in wild-type (WT) counterparts.
Bar, 5 mm. (E) RT-qPCR analysis demonstrates activation of fetal-specific genes (Myh7, Acta1, Nppa, and Nppb) in the CKO hearts. In
contrast, down-regulation of adult Myh6 is also observed. (F) Increased cell proliferation in CKO hearts (P1 and P5). Frozen tissue
sections were stained with anti-Ki-67, a marker of cell proliferation, and counterstained with DAPI. The percentage of proliferating
cells was calculated by dividing the number of Ki-67-positive nuclei by total nuclei and multiplying by 100.
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RT-qPCR demonstrated that expression of the fetal genes
Myh7, Acta1, Nppa, and Nppb is up-regulated in CKO
hearts (Fig. 2E). In contrast, adult gene Myh6 is down-
regulated. Mouse cardiomyocytes retain a small capacity
to proliferate after birth (Ahuja et al. 2007; Banerjee et al.
2007). To determine whether DOT1L deficiency results
in an increased cell proliferation, as exhibited in DCM,
heart tissue sections were immunostained for Ki-67 at P1
and P5. Results shown in Figure 2F demonstrate that the
percentage of proliferating cells (ratio of Ki-67-positive
nuclei to total nuclei, multiplied by 100) is significantly
increased in the CKO hearts compared with the control,
which may contribute to the observed increase in the
CKO heart mass. We note that this increased cell pro-
liferation in the DOT1L-deficient heart is in contrast to
previous studies showing a requirement for DOT1L in
embryonic stem cell cycle progression (Jones et al. 2008;
Barry et al. 2009), suggesting cell type specificity. Taken
together, the above data support the notion that CKO
hearts exhibit multiple phenotypes similar to those
observed in DCM.
CKO hearts exhibit similar functional defects
observed in DCM patients
To gain further support that DOT1L deficiency in car-
diomyocytes results in DCM, we asked whether the
morphological changes and cardiac remodeling observed
in CKO hearts affect their function. To this end, we
performed echocardiography (ECHO) analysis at different
mouse age groups. Conscious ECHOs performed on P10
pups during the first stage of lethality (n = 5 per genotype)
demonstrated that CKO mice have increased left ventric-
ular internal dimensions and volume. Analysis of cardiac
output by measuring ejection fraction (EF) and fractional
shortening (FS) revealed that both EF and FS is reduced by
almost half in CKO mice when compared with those of
wild-type mice (Table 1). These results are indicative of
left ventricular systolic dysfunction and are consistent
with clinical DCM outcome (Karkkainen and Peuhkurinen
2007; Luk et al. 2009). Similar results were obtained at
2 and 5 mo of age (Table 1). Interestingly, the smaller
difference between wild-type and CKO mice at 2 mo may
reflect a compensation that allowed these mice to bypass
the first stage of lethality.
Cardiac conduction abnormalities are frequently ob-
served in DCM heart failure patients with left ventricular
systolic dysfunction (Olson 2004). During heart contrac-
tion, an electrical impulse transmits from atria (P-wave)
to ventricles (QRS-wave) at the atrioventricular node
(AVN). The time delay for electrical propagation can be
measured directly by electrocardiography (EKG) (Hatcher
and Basson 2009). To determine whether the conduction
system is perturbed in CKO mice, EKG was performed at
5 mo of age (n = 8 per genotype). All CKO mice displayed
minimally a first-degree heart block at the AVN, with an
80% penetration of either nonsustained ventricular
tachycardia (n = 1 of 8) (Fig. 3A, CKOa), periodic third-
degree heart block (n = 3 of 8), or second-degree Type II
heart block (n = 3 of 8) (Fig. 3A, CKOb). Overall, CKO
mice have a significant increase in RR interval (Fig. 3B),
PR interval (Fig. 3C), P-wave duration (Fig. 3D), and QRS
interval (Fig. 3E). These EKG data from CKO mice are
consistent with EKG findings in human DCM patients
(Seidman and Seidman 2001; Towbin and Bowles 2006;
Luk et al. 2009). The physiological studies further support
the notion that DOT1L deficiency in cardiomyocytes
confers phenotypes similar to those observed in patients
with DCM.
Dot1L deficiency in cardiomyocytes down-regulates
dystrophin expression
Having established that DOT1L deficiency in cardiomyo-
cytes causes phenotypes similar to those observed in
DCM, we next attempted to understand the molecular
mechanism. To date, mutations in >30 genes have been
linked to human DCM (Supplemental Table 1) (Towbin
and Bowles 2006; Karkkainen and Peuhkurinen 2007;
Kimura 2008; Luk et al. 2009). Given that DOT1L-
mediated H3K79 methylation is associated with actively
transcribed genes (Martin and Zhang 2005; Z Wang et al.
2008), we anticipated that one or more of the DCM-
associated genes might be down-regulated due to loss of









(mL) LV mass n
P10
Wild type 89.20% 6 1.86% 56.50% 6 2.69% 1.59 6 0.13 0.70 6 0.08 7.23 6 1.58 0.79 6 0.28 18.70 6 3.01 5
CKO 55.80% 6 3.83% 27.30% 6 2.15% 2.16 6 0.25 1.57 6 0.23 15.79 6 4.82 7.15 6 2.87 21.41 6 3.47 5
P-value *** *** * *** * ** ns
2 mo
Wild type 85.15% 6 4.63% 53.47% 6 6.03% 2.73 6 0.19 1.27 6 0.18 27.97 6 4.66 4.11 6 1.46 76.61 6 11.88 6
CKO 72.56% 6 5.77% 40.81% 6 4.73% 3.12 6 0.13 1.85 6 0.20 38.83 6 4.12 10.87 6 2.91 98.51 6 18.0 4
P-value * * * ** * ** ns
5 mo
Wild type 84.73% 6 3.60% 52.74% 6 4.43% 2.98 6 0.28 1.41 6 0.19 35.01 6 7.72 5.36 6 1.81 87.16 6 13.89 10
CKO 47.02% 6 18.48% 24.44% 6 10.84% 4.91 6 1.43 3.85 6 1.60 127.58 6 83.67 80.83 6 70.08 205.86 6 101.11 7
P-value *** *** ** *** ** ** **
(EF) Ejection fraction; (FS) fractional shortening; (LVID) left ventricular internal diameter; (LV Vol) left ventricular volume; (LV mass) left
ventricular mass (AW) corrected; (d) end diastolic; (s) end systolic. (***) <0.0006; (**) <0.006; (*) <0.06; (ns) $0.06.
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H3K79 methylation in the CKO heart. To this end, we
performed four independent gene expression microarrays
using the dual-color Agilent 4X44K Whole Mouse Ge-
nome Array system. Data analysis revealed 751 down-
regulated probes representing 471 genes that are statisti-
cally significant, with a false-positive rate of 0.06%
(Supplemental Table 2). Comparison of the microarray
data with known DCM-associated genes identified two
common genes: Titin (Ttn) and Dystrophin (Dmd).
Ttn is a giant myofilament protein important for
maintaining sarcomere structure and elasticity (Kostin
et al. 2000). Mutations in Ttn have been reported in
autosomal dominant forms of familial DCM (Gerull et al.
2002). Mouse models expressing M-line-deficient Ttn
exhibit widened M-lines and gradual disassembly of
sarcomeres, which lead to cardiac failure (Gotthardt
et al. 2003; Weinert et al. 2006). If Ttn down-regulation
is responsible for the DCM in CKO mice, we anticipate
an abnormal sarcomere structure in DOT1L CKO hearts.
However, TEM analysis revealed that sarcomere integrity
is maintained in DOT1L CKO hearts (Supplemental Fig.
4), suggesting that down-regulation of Ttn is not a major
contributing factor for the DCM in DOT1L CKO mice.
Dmd was the first discovered DCM-associated gene
that can cause both DCM and muscular dystrophy. Dmd
is a membrane-associated protein that forms a dystro-
phin–glycoprotein complex (DGC), which connects con-
tractile sarcomeres to the sarcolemma and extracellular
matrix (ECM). This connection is vital for lateral force
transduction between cardiomyocytes, as well as for
relieving mechanical stress on sarcolemma during con-
traction (Kostin et al. 2000; Kimura 2008). Since a loss of
Dmd expression may be the cause of cell death and
cardiac remodeling observed in CKO hearts, we first
confirmed the microarray results by RT-qPCR. Data
presented in Figure 4A demonstrate that the Dmd mRNA
levels are down-regulated to ;25% of the wild-type level
in the CKO hearts. In contrast, expression of other
randomly selected DCM-relevant genes (Actn2, Ldb3,
Des, and Taz) was not significantly altered by DOT1L
deficiency (Fig. 4A). Consistent with a reduction at the
RNA level, immunostaining revealed that Dmd protein
level is also greatly diminished in CKO hearts (Fig. 4B,C).
Previous studies have demonstrated that mutations af-
fecting expression of Dmd or any sarcoglycan (Sgc) gene
lead to DGC instability and reduced levels of all com-
plex proteins (Deconinck et al. 1997; Grady et al. 1997).
Consistently, immunostaining revealed a great loss of
b-dystroglycan (bDG) and a-sarcoglycan (SGCA) proteins
in CKO mice (Fig. 4B,C), although none of the DGC
components is altered at the RNA level by DOT1L
deficiency (Fig. 4A). These results suggest that loss of
Dmd caused degradation of the DGC components, which
in turn affects cardiomyocyte viability.
We next sought to determine whether DOT1L directly
regulates Dmd expression in the mouse heart by chro-
matin immunoprecipitation (ChIP). Despite extensive
efforts, none of the homemade or commercial DOT1L
antibodies (Abgent AP1198a and AP1198b; Cell Signaling
D8891 and D8890; and Abcam ab7295) was able to de-
tect endogenous DOT1L protein (data not shown), and
thus they are unsuitable for ChIP. Therefore, we per-
formed ChIP assays across the Dmd locus using an anti-
H3K79me2/3 antibody. Results shown in Figure 4D
demonstrate that relatively less H3K79me2/3 is observed
upstream of the Dmd transcription start site (TSS), but it
greatly increases downstream, continues to rise at 20 kb
downstream from the TSS, and is still present as far as 59
kb downstream from the TSS. This H3K79me2/3 distri-
bution pattern is consistent with published ChIP-seq
results using various cell lines (Barski et al. 2007; Z Wang
et al. 2008). Importantly, the H3K79me2/3 enrichment on
the Dmd gene depends on functional DOT1L, as the
enrichment is abolished when samples derived from
Dot1L CKO hearts are used. In addition, the detected
signals are specific, as enrichment was not observed when
IgG was used in a parallel ChIP assay. Previous studies
have demonstrated that DOT1L deficiency leads to a
complete loss of H3K79 methylation (Jones et al. 2008),
indicating that DOT1L is the only H3K79 methyltrans-
ferase. The demonstration that H3K79 methylation of the
Dmd gene is dependent on functional DOT1L supports
the notion that Dmd is a direct DOT1L target.
It has been reported previously that Dmd expression is
positively regulated by the binding of the transcription
activator SRF (serum response factor) to a CArG-box
Figure 3. Disruption of DOT1L function
in mouse cardiomyocytes results in conduc-
tion abnormalities. (A) Representative
EKGs for wild-type (Wt) and CKO mice.
The analysis was performed using 5-mo-old
mice (n = 8 per group). CKOa has complete
AV dissociation, as evidence by nonsus-
tained ventricular tachycardia, while CKOb
has a Type II second-degree heart block. Bar,
200 msec. (B–E) Quantification of EKG data
indicated an overall significant increase in
RR interval (B), PR interval (C), P-wave
duration (D), and QRS interval (E). P-values
were calculated by Student t-test.
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consensus sequence within the muscle-specific Dmd
promoter (Galvagni et al. 1997). To examine whether
transcription activation by SRF is affected in CKO hearts,
we analyzed SRF RNA levels by RT-qPCR. The results
shown in Figure 4A demonstrate that SRF expression
is not significantly altered in CKO hearts (Fig. 4A). In
addition, ChIP analysis using an anti-SRF antibody in-
dicates that SRF binding to the TSS or CArG-box con-
sensus region of Dmd is not affected by Dot1L KO (Fig.
4E). These results support that DOT1L and SRF function
independently of each other, and that transcriptional
regulation of Dmd by DOT1L-mediated H3K79 methyl-
ation functions downstream from SRF.
DOT1L directly regulates dystrophin expression
in C2C12 cells
To further demonstrate that DOT1L directly regulates
Dmd expression, we performed lentiviral shRNA knock-
down (KD) and retroviral rescue experiments in C2C12
myoblast cells. KD of mDot1L effectively reduced both
mDot1L and Dmd expression compared with control
shRNA, whereas Srf is not significantly affected (Fig.
4F). Despite similar expression levels of the wild-type
and a catalytic mutant Flag-hDOT1L (Supplemental Fig.
6), Dmd expression is rescued only by wild-type Flag-
hDOT1L, but not the catalytic mutant, indicating that
DOT1L-mediated H3K79 methylation is critical for Dmd
expression (Fig. 4F). ChIP analysis demonstrates that the
effect of DOT1L on Dmd expression is direct, as both
wild-type and catalytic mutant Flag-hDOT1L bind to the
Dmd locus (Fig. 4G). Consistent with transcriptional
regulation of Dmd by DOT1L histone methyltransferase
activity, H3K79 methylation is also enriched at the Dmd
locus in control shRNA and wild-type Flag-hDOT1L res-
cued samples, while enrichment is reduced in mDOT1L
KD and catalytic mutant rescued cells (Fig. 4H). Thus,
these data establish that H3K79 methylation by DOT1L
directly regulates Dmd transcription.
Postnatal dystrophin gene delivery and expression
in cardiomyocytes rescues cardiac function
in CKO mice
Gene expression and ChIP analyses suggest that DOT1L’s
role in cardiomyocytes may be mediated through its
regulation of Dmd expression. To determine whether
Dmd is a key target contributing to the DCM phenotype,
we performed in vivo rescue experiments using an adeno-
associated virus serotype 9 (AAV9) vector expressing
a minidystrophin gene under the control of CMV pro-
moter. AAV-mediated gene therapy with minidystrophin
Figure 4. Dystrophin is a direct target of
DOT1L. (A) RT-qPCR analysis using RNAs
isolated from P10 wild-type (WT) and CKO
hearts (n = 12). Dmd and Ttn expression is
down-regulated in Dot1L CKO hearts.
Other members of the DGC (Dag1, Sgca,
Sgcb, Sgcd, and Sgcg), as well as selected
DCM causal genes (Actn2, Ldb3, Des, and
Taz), remain unchanged. (B,C) Immunos-
taining of frozen heart sections demon-
strated loss of Dmd protein in CKO hearts
(green). Consistent with a Dmd deficiency
and complex instability, reduction of bDG
(B) and SGCA (C) is observed. (D) Micro-
ChIP using heart tissues from P10 pups
demonstrates that H3K79me2/3 is enriched
in the gene body of Dmd, and the enrich-
ment is dependent on functional DOT1L.
Amplicon #1 located ;15 kb upstream of the
TSS serves as background for H3K79me2/3
enrichment. (E) ChIP using an anti-SRF
antibody demonstrates that SRF binding
to the CArG-box consensus region of the
Dmd muscle-specific promoter is not af-
fected in Dot1L CKO hearts. Amplification
at the 15-kb TSS serves as a background
for SRF enrichment. (F) RT-qPCR analysis
demonstrates that Dot1L KD in C2C12
cells results in down-regulation of Dmd.
Error bars represent SD of three indepen-
dent experiments. (G,H) ChIP analysis dem-
onstrates binding of F-DOT1L to the Dmd
locus, and its methylation on H3K79 is
dependent on DOT1L enzymatic activity.
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has been shown previously to effectively treat dystro-
phic pathology (Wang et al. 2000). The vector used
to rescue Dot1L CKO mice, rAAV9-CMV-DysD3990
(rAAV9-miniDmd), provides high expression of minidy-
strophin in all muscle tissues, including the heart (B
Wang et al. 2008). To rescue CKO mice, rAAV9-miniDmd
was administered at two different age groups— at either
P3 via intraperitoneal (i.p.) injection or 2 mo via tail vein
injection—and analyzed by ECHO. As shown in Table 2,
cardiac function (EF and FS) is restored in CKO rescued
mice injected at P3 (cf. Tables 1 and 2). Additionally,
increases in LVID, LV Vol, and LV mass are significantly
reduced by expression of minidystrophin (cf. Tables 1 and
2). Similar improvements were also observed in adult
mice rescued at 2 mo of age (cf. Tables 1 and 2). Most
significantly, adult rescued mice are able to survive past
the second stage of lethality with no impairments in
cardiac function (Table 2, 8 mo).
In addition to ECHO analysis, EKG of rescued CKO
mice was also analyzed. At 5 mo, during the second stage
of lethality, EKGs were obtained from mice rescued at P3.
The results demonstrate that RR interval (Fig. 5A), PR
interval (Fig. 5B), P duration (Fig. 5C), and QRS interval
(Fig. 5D) were restored in the CKO mice. For mice rescued
as adults, EKG was analyzed at 5 mo and 8 mo of age. The
RR interval (Fig. 5E), P duration (Fig. 5G), and QRS
interval (Fig. 5H) were restored in these mice, while PR
intervals improved partially (cf. P-values in Figs. 5B, and
3C). In addition, heart blocks observed prior to injection
were no longer present in rescued CKO mice, as indicated
by the EKG images and echocardiograms of the same
mice before and after treatment (Supplemental Fig. 6A,B).
Collectively, the above studies demonstrate that the
functional defects caused by DOT1L deficiency in car-
diomyocytes can be largely rescued by postnatal expres-
sion of Dmd, supporting that Dmd is a key DOT1L target
in cardiomyocytes.
Discussion
DOT1L is the only known H3K79 methyltransferase and
is conserved from yeast to humans. It is highly expressed
in the heart, blood cells, and testis, although its expres-
sion in mammals is ubiquitous. Germline KO of Dot1L
has been shown to be embryonic-lethal with cardiovas-
cular and hematopoietic defects. In this study, we dem-
onstrate that DOT1L H3K79 methyltransferase activity
is vital for cardiac function in the mouse using a cardiac-
specific KO model. DOT1L loss-of-function results in
postnatal and adult lethality from DCM and CHF.
The Dot1L CKO mouse is a useful model
for understanding DCM
Cardiac-specific loss of DOT1L H3K79 methyltransferase
activity caused gross changes in cardiac growth and shape
that are reminiscent of dilated cardiomyopathy. DCM is
a disease of the heart muscle characterized by enlarge-
ment of one or both heart chambers, eccentric hypertro-
phy, interstitial fibrosis, systolic dysfunction, and con-
duction defects. In this study, we show that Dot1L CKO
mice hearts are spherical in shape with enlarged chamber
volumes and increased mass. Through immunostaining,
we demonstrate that eccentric hypertrophy, increased
proliferation, and reactive fibrosis may contribute to the
increase in heart mass. In addition, a significant increase
in cellular apoptosis was observed in CKO hearts. Finally,
EKG and ECHO analyses revealed severe defects in









(mL) LV mass n
rAAV-Dmd at P3
2 mo
Wild type 85.85% 6 2.79% 53.43% 6 3.32% 2.57 6 0.23 1.20 6 0.18 24.25 6 5.29 3.54 6 1.31 75.83 6 8.52 5
CKO 79.53% 6 6.76% 46.97% 6 6.59% 2.77 6 0.35 1.48 6 0.36 29.59 6 9.75 6.51 6 4.12 82.19 6 14.13 4
P-value ns ns ns ns ns ns ns
5 mo
Wild type 83.00% 6 0.92% 50.40% 6 0.66% 2.90 6 0.33 1.44 6 0.17 32.70 6 9.43 5.64 6 1.82 78.30 6 15.62 5
CKO 78.47% 6 11.52% 47.81% 6 12.36% 3.10 6 0.46 1.66 6 0.60 39.38 6 14.11 9.51 6 7.08 103.62 6 29.65 4
P-value ns ns ns ns ns ns ns
rAAV-Dmd at 2 mo
5 mo
Wild type 73.47% 6 17.81% 42.62% 6 14.20% 2.79 6 0.22 1.62 6 0.54 29.57 6 6.05 8.61 6 7.53 78.83 6 6.95 3
CKO 82.87% 6 3.53% 50.39% 6 4.07% 2.81 6 0.12 1.40 6 0.16 30.04 6 3.14 5.27 6 1.54 104.25 6 9.60 3
P-value ns ns ns ns ns ns ns
8 mo
Wild type 88.29% 6 1.03% 57.14% 6 1.21% 3.12 6 0.25 1.34 6 0.14 38.69 6 7.38 4.57 6 1.24 84.01 6 18.93 3
CKO 83.32% 6 2.13% 50.97% 6 2.22% 3.15 6 0.25 1.55 6 0.20 40.30 6 8.67 6.87 6 2.44 120.48 6 19.58 3
P-value ns ns ns ns ns ns ns
To perform postnatal rescue, pups at P3 were administered rAAV-Dmd via intraperitoneal injection. To perform adult rescue, mice
at 2 mo of age were administered rAAV-Dmd via tail vein injection. (EF) Ejection fraction; (FS) fractional shortening; (LVID) left
ventricular internal diameter; (LV Vol) left ventricular volume; (LV mass) left ventricular mass (AW) corrected; (d) end diastolic; (s)
end systolic.
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cardiac force transmission and output. Collectively, these
data support that loss-of-function of DOT1L in cardio-
myocytes results in phenotypes similar to those observed
in DCM patients, making our mouse a valuable model for
understanding DCM.
Dystrophin is a key target mediating DOT1L function
in the heart
As the only known H3K79 methyltransferase, DOT1L is
thought to play a genome-wide role in transcriptional
regulation. Therefore, it may be inferred that loss of
DOT1L enzymatic activity would silence a large number
of genes vital for cardiac function. Microarray analysis
revealed 751 down-regulated probes corresponding to 471
genes in CKO hearts. However, only two of these genes
have been directly linked to DCM in mice and humans:
Ttn and Dmd. Our histopathology data, including myo-
cyte loss and remodeling, are consistent with a Dmd
deficiency (Heydemann and McNally 2007) and not loss
of Ttn, since sarcomeres remain normal.
We demonstrate that cardiac Dmd expression corre-
lates with DOT1L-mediated H3K79 methylation. In
addition, we show that DOT1L methyltransferase activ-
ity regulates Dmd transcription in C2C12 myoblast cells,
and that exogenous Flag-DOT1L is localized to the Dmd
locus. Collectively, these data conclusively demonstrate
that DOT1L is a transcriptional regulator directly in-
volved in Dmd expression. While other genes regulated
by DOT1L may contribute to the DCM phenotype
observed in CKO mice, the fact that the cardiac func-
tional defects can be rescued by expression of a minidy-
strophin supports that Dmd is a critical target mediating
DOT1L function in the heart.
In the mdx mouse, a nonsense mutation results in the
loss of Dmd expression in all muscle cells. Surprisingly,
these mice do not develop severe DCM phenotypes
(Hoffman et al. 1987; Grady et al. 1997), while DOT1L
deficiency-caused Dmd down-regulation does. Since the
DOT1L deficiency in CKO mice occurs only in cardio-
myocytes, Dmd expression is retained in CKO skeletal
muscle, allowing for normal levels of exercise. The
increased exercise in CKO mice compared with mdx
mice causes additional workload and stress on the heart,
which would escalate the severity of DCM. Indeed, it has
been reported that targeted repair in mdx mice using a
skeletal muscle-restricted minidystrophin transgene sig-
nificantly enhanced cardiac injury and DCM (Townsend
et al. 2008).
The apparent inconsistency between CKO and mdx
mice can also be explained by the lack of a similar
compensation mechanism. Previous studies have dem-
onstrated that loss of Dmd expression in the mdx mouse
is compensated by up-regulation of Utrophin (Utrn), an
autosomal Dmd homolog (Deconinck et al. 1997; Grady
et al. 1997). However, this compensation mechanism
does not seem to exist in CKO mice, as DOT1L de-
ficiency did not cause up-regulation of Utrn (Supplemen-
tal Fig. 5). Thus, the Dot1L CKO mouse may serve as
a useful model for comparative analysis of the molecular
mechanisms underlying the regulation of Utrn.
A potential link between DOT1L and DCM/Duchenne
muscular dystrophy (DMD)
CHF is a common manifestation of cardiomyopathy,
a disease caused by malfunction of the heart muscle
(Seidman and Seidman 2001; Liew and Dzau 2004).
DCM is the most common form of cardiomyopathy, af-
fecting 36.5 out of 100,000 people (Seidman and Seidman
2001; Liew and Dzau 2004; Luk et al. 2009). Although
extensive work has been performed to identify signature
DCM genes through global expression profiling (Barrans
et al. 2002; Barth et al. 2006; Camargo and Azuaje 2008),
little effort has been focused on the epigenetic contribu-
tion, with the exception of histone acetylation (Zhang
et al. 2002; Kook et al. 2003; Montgomery et al. 2007; Ha
et al. 2010; Hang et al. 2010). With regard to histone
Figure 5. Rescue of electrical conduction
in CKO mice by expression of minidystro-
phin gene. (A–D) The defective function of
the CKO heart can be rescued by expression
of a minidystrophin gene when injected at
P3 and analyzed at 5 mo of age, as indicated
by the lack of significant difference be-
tween wild-type (WT) and CKO rescued
mice. (E–H) Additionally, minidystrophin
can rescue adult CKO mice injected at
2 mo in terms of RR interval (E), P-wave
duration (G), and QRS interval (H). (F) In
addition, PR interval was partially rescued,
as the difference observed is less than
without miniDmd. (P = 0.02 with rescue
vs. P = 0.00014 [Fig. 3C] without rescue at
5 mo). (E,F) At 8 mo of age, past the second
stage of lethality, CKO + miniDmd mice
still maintain similar rescued levels of
electrical conduction performance.
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methylation, only two studies have investigated changes
in methylation patterns in heart failure (Kaneda et al.
2009; Movassagh et al. 2010). However, whether it di-
rectly contributes to the development of DCM is not
known.
The demonstration that loss of DOT1L enzymatic
activity results in DCM not only establishes a connection
between dysregulation of histone methylation to DCM,
but also raises the possibility that malfunction of DOT1L
might account for some DCM patients. To explore this
possibility, we analyzed hDOT1L expression level in
idiopathic DCM (n = 27) and normal (n = 11) myocardial
samples from publically available microarray data (http://
cardiogenomics.med.harvard.edu/project-detail?project_
id=229). This analysis indicates that DOT1L is down-
regulated in idiopathic DCM patients with all Affymetrix
probe sets (n = 11 probes per set) (Supplemental Fig. 8),
supporting the notion that dysfunction of DOT1L may be
a contributing factor to human idiopathic DCM. Muta-
tions in Dmd is also the cause of both DMD and Becker
muscular dystrophy (BMD), affecting one out of 3500
males (Hoffman et al. 1987). Up to 90% of those patients
manifest cardiomyopathies, and many die of heart failure
(Connuck et al. 2008). In this study, we established that
DOT1L regulates Dmd expression in both cardiac and
C2C12 cells, suggesting that a DOT1L deficiency may
contribute to DCM and human muscular dystrophy.
Future studies should reveal whether DOT1L is geneti-
cally linked to DCM, DMD, and BMD in human patients.
Materials and methods
Generation of cardiac-specific Dot1L CKO mice
The targeting vector and generation of DOT1L chimeric mice
have been described previously (Jones et al. 2008). DOT1L2lox/+
and DOT1L1lox/+ mice were mated with a-MHC-Cre+/+
transgenic mice to obtain DOT1L2lox/+;a-MHC-Cre+/+ and
DOT1L1lox/+;a-MHC-Cre+/+ mating pairs. Mice were kept on
a 129SvJ, C57BL/6J mixed background. DOT1L2lox/1lox;a-MHC-
Cre+/+ mice and DOT1L2lox/2lox; a-MHC-Cre+/+ mice were used
as CKO mice. Upon Cre recombination, exons 5 and 6 were
excised from the DOT1L locus. After splicing of the DOT1L
transcript from the CKO allele, exons 4 and 7 of the mature
mRNA were translated in-frame, generating a mutant DOT1L
protein lacking a portion of the SAM-binding motif. All mice
procedures were performed following the guidelines set by the
Institutional Animal Care and Use Committee.
ECHO and EKG
Experiments were performed at the Mouse Cardiovascular
Models Core Facility at University of North Carolina at Chapel
Hill (UNC-CH) or in the laboratory of Dr. Xiao Xiao (UNC-CH).
To restrain postnatal pups, paws were taped to a plastic board.
For adult mice, soft cotton thread loops were placed around each
leg, just proximal to the paw, and gently snugged with a plastic
slider. The distal ends of the threads were placed in notches cut
into a plastic board and gently tightened to hold the animal in
a supine position to prevent self-mutilation of the forelimbs.
Warmed Aquasonic gel was applied over the thorax and a 30-
MHz probe was positioned over the chest in a parasternal
position. Long and short axis B-mode and M-mode images were
recorded. Upon completion of the procedure, the gel was wiped
off and the animal was returned to its cage housed in a warm
chamber. Time of restraint was 5 min or less. For EKG, mice
were anesthetized with inhaled isoflurane. Mice were taped to
a warmed mouse board and their body temperature was moni-
tored with a rectal probe and maintained at 37°C 6 1°C
throughout the procedure. Thin (29 gauge) sharpened needle
electrodes were passed subcutaneously into the area at the
ventral base of each limb. After three leads were recorded, the
needles were removed and the animals were allowed to recover.
Histology and immunofluorescence staining
For all tissue sectioning, beating hearts were harvested from
euthanized mice and immediately transferred to ice-cold PBS
containing 1 M KCl until the hearts stopped beating at diastole
state. For H&E staining, hearts were fixed in 4% paraformalde-
hyde overnight and paraffin-embedded. Serial sections at 5-mm
thickness were used for staining. Hearts used for all immuno-
fluorescence staining were fixed in 4% PFA and subjected to
sequential incubation with 10%, 20%, and 30% sucrose in PBS
at 4°C. Hearts were then flash-frozen in OCT medium using
liquid nitrogen, and frozen serial sections of 5-mm thickness
were prepared using a Leica Cryostat. Primary antibodies used
for staining include anti-Dystrophin (Abcam, ab15277-500), anti-
HSPG2 (Neomarkers, RT-794), anti-a-Laminin (Chemicon,
AB2034), anti-H3K79me2/3 (Abcam, ab2621-100), and anti-
Ki-67 (Abcam, ab15580). Secondary antibodies used were Alexa
Fluor 594 goat anti-rat IgG (Invitrogen, A21212), Alexa Fluor 594
donkey anti-rabbit IgG (Invitrogen, A21207), and Alexa Fluor 488
donkey anti-rabbit IgG (Invitrogen, A21206). Sections were
counterstained with DAPI.
TUNEL assay
TUNEL staining was performed on frozen sections using the
ApopTag Fluorescein In Situ Apoptosis Detection kit (Millipore,
S7110) and counterstained with DAPI.
Masson’s trichrome staining
Paraffin sections, 5 mm thick, of hearts from 5-mo-old mice were
used for staining. Masson’s Trichrome Stain kit was purchased
from Dako (AR173), and procedures were followed according to
the manufacturer’s specifications, manually, without an Artisan
staining system.
TEM
Wild-type and CKO mice were injected with 25 U of heparin
intramuscular prior to euthanasia by isofluorane overdose. The
hearts were quickly exposed and perfused with 3 mg/mL
2,3-Butanedione monoxime in Hepes-buffered Krebs solution,
followed by perfusion with 2% glutaraldehyde plus 6% sucrose
in 75 mM Na-Cacodylate buffer (pH 7.4) supplemented with
3 mg/mL BDM and 0.1% tannic acid, followed by 2% osmium
tetroxide. Samples were stained with uranyl acetate en bloc. Images
were acquired on a Zeiss EM 910 transmission electron microscope
using a Gatan SC1000 digital camera.
Microarray and RT-qPCR analysis
Hearts were flash-frozen in liquid nitrogen and ground to a fine
powder. Total RNA was purified from tissue powder using the
Qiagen RNeasy kit. RNA from three hearts, 1 ug each, was
pooled together. Four pairs of pooled RNA, representing a total of
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12 wild-type and 12 CKO hearts, were used for gene expression
analysis. Samples were submitted to the UNC Genomics and
Bioinformatics Core Facility for RNA labeling, amplification,
hybridization, and scanning. The dual-color Agilent 4X44K
Whole Mouse Genome Array system was used. All reagents
were purchased from Agilent, and procedures were followed
according to Agilent’s protocols. Raw data were uploaded into
the UNC Microarray Database (Agi-Scanner-Reg-MM-4X44K-
D20060807-BARCODE14868; Slide Run US82800149). Data
were analyzed using the SAM algorithm (tail strength 51.4%,
SE 63.8%) to yield 1379 significant probes with a median number
of false positives (0.81) and a false discovery rate of 0.06%. For
RT-qPCR analysis, RNA prepared above was treated with DNase
I, and first strand DNA synthesis was performed using Improm II
(Promega). SYBR GreenER qPCR SuperMix (Invitrogen) was used
for qPCR. Relative expression was normalized to gapdh. Primers
are shown in Supplemental Table 3.
Micro-ChIP and Western blot
Micro-ChIP from frozen heart biopsies was performed as de-
scribed previously (Dahl and Collas 2008) with the following
modifications. Frozen hearts from P10 pups were ground to a fine
powder prior to formaldehyde cross-linking. DNA was frag-
mented into 300–500 base pairs (bp) by sonication at 15% power
(2 3 15 sec, 0.5 sec on and 2 sec off). Immunoprecipitation was
performed using anti-H3K79me2/3 (Abcam) and anti-rabbit IgG
(Santa Cruz Biotechnology, sc-2027). Chromatin immunoprecip-
itated samples were washed twice with low-salt (140 mM NaCl)
RIPA buffer, once with high-salt (500 mM NaCl) RIPA buffer, and
twice with TE buffer. DNA was purified using the Chelex-100
method, and qPCR was performed using the ChIP primers listed
in Supplemental Table 3. For Western blot analysis, P1 frozen
hearts were ground to a fine powder for histone extraction and
Western blot as described previously (Fang et al. 2002).
C2C12 KD and rescue
C2C12 cells were maintained in Dulbecco’s modified Eagle’s
medium supplemented with 10% FBS and 1% penicillin/strep-
tomycin. To establish stable KD cell lines, the lentivirus pTY-
EF1a system was used as described previously (Cao et al. 2008;
He et al. 2008). To knock down mDOT1L, a shRNA 19mer was
designed targeting the coding region (59-GGAGCCAGATCTCA
GAGAA-39). The control shRNA is targeted against a bacterial
protein with no mouse or human homology (59-GTTCAGATGT
GCGGCGAGT-39). KD cells were selected and maintained in
medium containing 2 mg/mL puromycin. For rescue experiments,
KD cells were infected with retrovirus expressing wild-type and
catalytic mutant Flag-tagged human DOT1L (Flag-hDOT1L) as
described previously (Okada et al. 2005). Retrovirus-infected cells
were selected and maintained in medium containing 2 mg/mL
blasticidin. RNA was isolated using RNeasy kit from Qiagen.
The same micro-ChIP procedure described above was followed
for ChIP using 50,000 cells per sample. Dynabeads Protein A and
M2 Flag antibody (Sigma, F3165) were also used.
Postnatal rescue of CKO mice with rAAV-miniDmd
The functional miniature version of human dystrophin gene
D3990 (miniDmd) under the transcriptional control of CMV
promoter has been described previously (Wang et al. 2000). The
miniDmd gene expression cassette was packaged into AAV9
vector using the helper-free, triple plasmids transfection method
and was purified by double CsCl density ultracentrifugation
(Xiao et al. 1998). The rAAV9-CMV-miniDmd titers were de-
termined by DNA dot blot at ;1 3 1013 viral genome (v.g.)
particles per milliliter. For 3-d-old neonatal CKO mice, a single
dose of 1 3 1011 v.g. per mouse in 50 mL was injected i.p. For
2-mo-old CKO mice, a single dose of 1 3 1012 v.g. per mouse in
600 mL was injected via tail vein.
Statistics
Indicated P-values were calculated using a two-tailed t-test.
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